50th week of 2009 patent applcation highlights part 53 |
Patent application number | Title | Published |
20090306018 | Skin conditioner - Moisture retention ability of skin is improved and/or skin is protected or treated for another purpose by applying thereto a composition containing at least one of the following compounds: ethanolamine, 2-methoxyethylamine, O-phosphorylethanolamine, 2-ethylaminoethanol, diethanolamine, 2-dimethylaminoethanol, choline, 2-amino-2-hydroxymethyl-1,3-propanediol, noradrenalin, phenethylamine, ethylenediamine, taurine, phosphatidylethanolamine, N-(2-hydroxyethyl)acetoamide, 2-(methylamino)ethanol, 2-anilinoethanol, 2-(benzylamino)ethanol, 3-amino-1-propanol, 2-amino-1-butanol, putrescine, DL-pyroglutamic acid and triethanolamine. | 2009-12-10 |
20090306019 | Compositions for treatment of eosinophilia and related disorders - The present invention discloses compositions comprising phosphatidic acid and uses thereof for the treatment of subjects suffering from eosinophilia or related disorders such as asthma and/or the prevention of these disorders in subjects having environmental or genetic predisposition thereto. | 2009-12-10 |
20090306020 | Combination therapy comprising diaryl ureas for treating diseases - The present invention relates to pharmaceutical compositions and combinations for treating cancer, comprising a diaryl urea compound and an PI3K/AKT signaling pathway inhibitor. Useful combinations include e.g. BAY-43-9006 as a diaryl urea compound. | 2009-12-10 |
20090306021 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS - The disclosure provides compounds and methods to treat bacterial pathogenesis, and demonstrates that the | 2009-12-10 |
20090306022 | 7-SUBSTITUTED TETRACYCLINE COMPOUNDS - The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression. | 2009-12-10 |
20090306023 | STABLE ORGANIC PEROXIDE COMPOSITIONS - Benzoyl peroxide compositions containing antioxidants and/or malonic acid. Treatment of acne vulgaris with a combination of actives, namely benzoyl peroxide and salicylic acid, include applying such benzoyl peroxide compositions to an area of the body afflicted with acne followed by application of a topical, at least partially neutralized salicylic acid composition to the afflicted area. Malonic acid may be included in combination with either the benzoyl peroxide composition, the salicylic acid composition or both. | 2009-12-10 |
20090306024 | Combination preparations of o-acetylsalicylic acid salts - The present invention relates to a fixed combination comprising a salt of o-acetylsalicylic acid with a basic amino acid as component A and an HMG-CoA reductase inhibitor as component B, a medicament comprising this combination and a process for its production. | 2009-12-10 |
20090306025 | Method and composition for skin inflammation and discoloration - The invention provides a method and compound for treating darkness and/or swelling/inflammation of the skin of humans. An antihistamine compound and a non-steroidal anti-inflammatory drug (NSAID) compound in combination have been found to effectively treat under eye darkness, swelling and puffiness in particular, when applied topically to the affected skin. | 2009-12-10 |
20090306027 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF G-PROTEIN BETA 3 SUBUNIT POLYMORPHISM - The invention provides methods for treating various indications and diseases in a patient in need thereof, wherein the patient has a C825T polymorphism in the G protein beta3 subunit (GNB3), comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate. | 2009-12-10 |
20090306028 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS - The present disclosure relates to methods of treating inflammatory disorders by administering a Syk inhibitory 2,4-pyrimidinediamine compound and an anti-inflammatory agent. | 2009-12-10 |
20090306029 | PROCESS FOR THE PREPARATION OF STERILE POWDERED PHARMACEUTICAL COMPOUNDS - The invention relates to a process for the preparation of pharmaceutical powders, the process comprising: a) solubilization of the pharmaceutical compound in water or in an organic solvent at a concentration close to saturation; b) evaporating the solvent at constant temperature while subjecting the solution to ultrasound. In another embodiment, the invention relates to a process for the preparation of sterile pharmaceutical compounds, the process comprising: a) solubilization of the pharmaceutical compound in water or in an organic solvent at a concentration close to saturation; b) sterilizing filtration of the solution by passing it through a hydrophobic filter (0.22 microns membrane); c) evaporating the solvent at constant temperature while subjecting the solution to ultrasound. | 2009-12-10 |
20090306030 | Methods Of Inhibiting Osteoclast Activity - Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. According to the methods, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Pharmaceutical compositions which comprise TRANCE/RANK inhibitor in an amount effective to inhibit osteoclastogenesis. Methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual are disclosed. The methods comprise the step of administering to the individual an amount of a TRANCE/RANK inhibitor effective to modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems. | 2009-12-10 |
20090306031 | 5alpha-ANDROSTANE-3,6,17-TRIONE (KNELLER'S TRIONE) AND METHODS OF USE THEREFOR - Disclosed are compounds such as 5α-androstane-3,6,17-trione, formulations comprising said compounds, and methods of use thereof to stimulate endogenous testosterone production and improve athletic performance and libido. | 2009-12-10 |
20090306032 | Use of solid lipid nanoparticles Comprising Cholesteryl Propionate and/or Cholesteryl Butyrate - The present invention refers to the use of solid lipid nanoparticles (SLN) obtained from warm microemulsions, containing cholesteryl propionate and/or cholesteryl butyrate, for preparation of a medicament for the prevention and treatment of vascular or inflammatory pathologies. | 2009-12-10 |
20090306033 | NOVEL CYCLIC PEPTIDES - Compounds are disclosed of general formula (I): | 2009-12-10 |
20090306034 | USE OF PICOPLATIN TO TREAT COLORECTAL CANCER - The invention provides a method of treatment of colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with 5-FU and leucovorin in a variety of treatment regimens. | 2009-12-10 |
20090306035 | Compounds and Methods for modulating the Silencing of a Polynucleotide of Interest - Methods and compositions comprising chemical compounds that modulate the silencing of a polynucleotide of interest in a cell are provided. Such chemical compounds when used in combination with an appropriate silencing element can be used to modulate (increase or decrease) the level of the polynucleotide targeted by the silencing element. Methods of using such compositions both in therapies involving RNAi-mediated suppression of gene expression, as well as, in vitro methods that allow for the targeted modulation of expression of a polynucleotide of interest are provided. Pharmaceutical or cosmetic formulations comprising such compounds and silencing elements also are disclosed. Methods for screening a compound of interest for the ability to modulate the activity of a heterologous silencing element also are provided. | 2009-12-10 |
20090306036 | METHODS OF SCREENING AGENTS, CONJUGATES OR CONJUGATE MOIETIES FOR TRANSPORT BY A PEPT2 TRANSPORTER - The invention provides methods of screening agents, conjugates or conjugate moieties, linked or linkable to agents, for capacity to be transported as substrates through the PEPT2 transporter. The invention also provides methods of treatment involving delivery of agents that either alone, or as a result of linkage to a conjugate moiety, are substrates of the PEPT2 transporter. The invention also provides conjugates comprising a pharmaceutical agent which is linked to a conjugate moiety that is a substrate for a PEPT2 transporter. | 2009-12-10 |
20090306037 | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity - The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor and a particular cannabinoid CB?1#191 receptor antagonist/inverse agonist, kits containing such combinations and methods of using such compositions for the treatment of diabetes, diabetes associated with obesity, diabetes-related disorders, obesity, and obesity-related disorders. | 2009-12-10 |
20090306038 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity - 2-Aminopyrimidine derivatives of formula (I) that are useful as modulators of the H | 2009-12-10 |
20090306039 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb). | 2009-12-10 |
20090306040 | Mono and Combination Therapy of M1/M4 Agonist (Sabcomeline) for Treatment of Negative Symptoms of Schizophrenia - The invention relates to the use of a functional muscarinic M1/M4 receptor agonist or a pharmaceutically acceptable salt thereof for the treatment of negative symptoms of schizophrenia. It also relates to adjunctive and simultaneous combination therapies for the treatment of negative symptoms of schizophrenia in which the functional muscarinic M1/M4 receptor agonist or a pharmaceutically acceptable salt thereof, in particular sabcomeline or a pharmaceutically acceptable salt thereof and at least one neuroprotective agent, neuroleptic and/or atypical antipsychotic agent are administered adjunctively or simultaneously. The invention also provides methods of treatment of the negative symptoms of schizophrenia utilising such therapies and such adjunctive or simultaneous therapeutic combination therapies, therapeutic combinations for use therein and pharmaceutical compositions comprising them. | 2009-12-10 |
20090306041 | Inhibitors of Bruton's tyrosine kinase - This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives according to generic Formulae I-III: | 2009-12-10 |
20090306042 | Novel Compounds 010 - The present invention provides compounds of formula (I) | 2009-12-10 |
20090306043 | PYRROLIDINE ETHER DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula I | 2009-12-10 |
20090306044 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES - The present invention relates to the use of quinazolines of formula (I), wherein the groups R | 2009-12-10 |
20090306045 | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease - The present invention relates to the use of glycogen synthase kinase 3(GSK3) inhibitors, especially inhibitors of GSK-3α, GSK-3β and GSK-3β2, preferably, inhibitors of GSK-3β, in patients having autoimmune diseases and/or immune dysfunction/dysregulation to induce immune tolerance. Inhibition of GSK leads to activation of a pathway of dendritic cell maturation which leads to a dendritic phenotype which attenuates, rather than induces, immune responses. The immune responses and mature dendritic cells produced by the method of the present invention redirect or attenuate the immune response in individuals, thus leading to effective therapies for a number of autoimmune diseases and/or diseases of immune dysfunction/dysregulation (immune inflammatory diseases), including systemic lupus erythematosus (SLE), autoimmune diabetes (type I diabetes mellitus), asthma, rheumatoid arthritis, inflammatory bowel disease, among numerous others. | 2009-12-10 |
20090306046 | METHOD OF TREATMENT OF HORMONE DEPLETION INDUCED VASOMOTOR SYMPTOMS - The invention provides a method to effectively wean a woman from hormone therapy for treatment of vasomotor symptoms by reducing the dosage of the hormonal agent to zero, while a non-hormonal drug in an amount, which is therapeutically effective for treating vasomotor symptoms, is administered or initiated and continued for a limited period of a duration between 3 and 8 months. | 2009-12-10 |
20090306047 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS - Disclosed are compounds of the formula I | 2009-12-10 |
20090306048 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES - A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome. | 2009-12-10 |
20090306049 | Treatment of Barrett's Esophagus - The invention relates to the field of biochemistry and medicine. More specifically, the invention relates to the treatment of epithelial changes in the esophagus. Even more specific, the invention relates to the treatment of Barrett's esophagus. The invention provides a method for at least in part decreasing Barrett's esophagus present in an animal comprising at least in part inhibiting Notch pathway activation in said animal. Preferably, said inhibition of Notch pathway activation is accomplished via a g-secretase inhibitor. | 2009-12-10 |
20090306050 | TREATMENT AND PREVENTION OF DEPRESSION WITH PAIN, DEPRESSION SECONDARY TO PAIN, AND OF NEUROPATHIC PAIN - In accordance with the present invention, it has been discovered that compounds exhibiting activity as a potent noradrenaline reuptake inhibitor (e.g., a NA: 5HT ratio of greater than or equal to about 1000:1), and activity at the dopamine D2 receptor sites (e.g., lofepramine) are effective in the treatment and prevention of various diseases and disorders associated with noradrenaline reuptake, such as pain predominant-type depression, depression secondary to chronic or neuropathic pain, and neuropathic pain itself. | 2009-12-10 |
20090306051 | Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders - The present invention relates to methods and compositions for treating CNS-related disorders. | 2009-12-10 |
20090306052 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - The present invention relates to novel indenyl derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders. | 2009-12-10 |
20090306053 | Highly selective rho-kinase inhibitor - The present invention relates to a compound having a highly selective Rho-kinase inhibiting activity and being useful as a therapeutic agent for a disease such as hypertension, pulmonary hypertension, cerebral vasospasm, cardiac angina, cardiac failure, arteriosclerosis, glaucoma, dysuria, asthma, or erectile dysfunction, and a drug containing the compound. | 2009-12-10 |
20090306054 | INTEGRASE INHIBITORS - Tricyclic compounds of formulae I-III, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed. | 2009-12-10 |
20090306055 | PHENYLAZOLE COMPOUNDS, PRODUCTION PROCESS AND ANTIOXIDANTS - The present invention is directed to compounds represented by the formula (1): | 2009-12-10 |
20090306056 | PYRROLO-PYRIDINE KINASE MODULATORS - The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity. | 2009-12-10 |
20090306057 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS - The invention is directed to [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus. | 2009-12-10 |
20090306058 | Sulphone Derivatives for Treatment of Cancer - Compounds of Formula (I) are disclosed for treatment of cancer. | 2009-12-10 |
20090306059 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP - A compound having the general formula (I), pharmacologically acceptable salts thereof or prodrugs thereof: | 2009-12-10 |
20090306060 | METHOD FOR IMPROVING SEED LOT QUALITY - The present invention relates to a method for improving seed lot quality, seed shelf life, and seed lot retention, comprising applying to a seed within the seed lot an effective amount of a strobilurin fungicide alone, or in combination with at least one additional fungicide. In a preferred embodiment, the additional fungicide is at least one phenylpyrrole type fungicide and/or at least one phenylpyrrole type fungicide. | 2009-12-10 |
20090306061 | FUNGICIDAL COMBINATIONS COMPRISING A GLYOXALIC ACID METHYL ESTER-O-METHYLOXIME DERIVATIVES - A method of combating phytopathogenic diseases on crop plants which comprises applying to the crop plants or the locus thereof being infested with said phytopathogenic disease an effective amount of a combination of
| 2009-12-10 |
20090306062 | 2,5-Disubstituted Piperidines - The application relates to 2,5-disubstituted piperidines, their preparation and use as medicines, especially as renin inhibitors, of the general formula (I) in which R, R | 2009-12-10 |
20090306063 | Oxadiazoanthracene Compounds For The Treatment Of Diabetes - The present invention provides oxadiazoanthracene derivatives of the formula (I), | 2009-12-10 |
20090306064 | Substituted Piperidines as Renin Inhibitors - Compounds of the general formula (I) in which the meanings of the substituents R | 2009-12-10 |
20090306065 | AEROSOL FORMULATION FOR INHALATION CONTAINING AN ANTICHOLINERGIC AGENT - The invention relates to specific aqueous aerosol formulations that are devoid of propellant, containing one or more anticholinergic agents of formula (1), in which X represents an anion, and containing at least one pharmacologically compatible organic acid and optionally additional pharmacologically compatible adjuvants and/or complexing agents. The cation of formula (1′) is contained in the preparation at a concentration of between 83 and 94.5 mg per 100 ml of medicament preparation. | 2009-12-10 |
20090306066 | PEPTIDE DEFORMYLASE INHIBITORS - The present invention is directed to certain {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I): | 2009-12-10 |
20090306067 | 2, 4-DIAMINOPYRIMIDIDE DERIVATES AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention encompasses compounds of general formula (1) wherein Q and R | 2009-12-10 |
20090306068 | NOVEL ENANTIOMERIC PURE BETA AGONISTS, MANUFACTURING AND USE AS A MEDICAMENTS THEREOF - The present invention relates to enantiomerically pure compounds of formula 1 | 2009-12-10 |
20090306069 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES - The present invention is related to azolidinedione-vinyl fused-benzene derivatives of formula (I) for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries. | 2009-12-10 |
20090306070 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE - The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers. | 2009-12-10 |
20090306071 | Inhibitors of Janus Kinases - The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer. | 2009-12-10 |
20090306072 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES - A method of treating inflammatory diseases of the airways or intestines which comprises administering substances selected from the group consisting of:
| 2009-12-10 |
20090306073 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers - Thiazole and thiophene compounds are disclosed having utility in treating inflammatory conditions, immunoinflammatory conditions, autoimmune diseases, and cancers. Methods for the synthesis of these compounds are also disclosed. | 2009-12-10 |
20090306074 | THIAZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS - Invented is a method of inhibiting the activity/function of PI3 kinases using thiazolidinedione derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of thiazolidinedione derivatives. | 2009-12-10 |
20090306075 | CHEMICAL COMPOUNDS - Compounds of formula (I): | 2009-12-10 |
20090306076 | Morpholine Carboxamide Prokineticin Receptor Antagonists - The present invention is directed to morpholine carboxamide compounds which are antagonists of prokineticin receptors, in particular antagonists of prokineticin 2 receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which prokineticin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which prokineticin receptors are involved. | 2009-12-10 |
20090306077 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE - The present invention relates to a study on the synthesis of a novel N-(2-aminophenyl)benzamide derivative having an urea structure and represented by the general formula (1); and the utilization of a pharmacological effect of the derivative. A compound represented by the general formula (1) or a salt thereof has an effect of cellular morphological change on trabecular meshwork cells and is effective in the prevention and/or treatment of a disease considered to be related to intraocular pressure. In the formula, R | 2009-12-10 |
20090306078 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT - Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient. The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity against HIF-1, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer; stomach cancer and breast cancer. Also, the compound having inhibition activity against HIF-1 is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HIF-1-mediated VEGF expression. | 2009-12-10 |
20090306079 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS - There are disclosed compounds of the formula | 2009-12-10 |
20090306080 | VETERINARY FORMULATION - The present invention relates to a liquid veterinary formulation comprising a stable solution of cyromazine, or a pharmaceutically acceptable salt thereof, in a solvent system which may comprise water and one or more polyethylene glycols. A liquid concentrate is also described in which the cyromazine, or a pharmaceutically acceptable salt thereof, may be dissolved in a liquid PEG and is capable of being diluted with water before use. | 2009-12-10 |
20090306081 | Solid Dosage Formulations of Hydralazine Compounds and Nitric Oxide Donor Compounds - The invention provides solid dosage formulations, methods of making and using the formulations comprising at least one hydralazine compound or a pharmaceutically acceptable salt thereof, and at least one excipient or carrier, wherein the formulations have less than about 0.001% to about 0.1% of a hydrazone compound based on the total weight of the formulation. The invention also provides solid dosage formulations, methods of making and using the formulations comprising at least one hydralazine compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor compound or a pharmaceutically acceptable salt thereof and at least one excipient or carrier, wherein the formulations have less than about 0.001% to about 0.1% of a hydrazone compound based on the total weight of the formulation. | 2009-12-10 |
20090306082 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, a diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxides, pharmaceutically acceptable solvates thereof and the pharmaceutical compositions containing them which are useful in the treatment of allergic and inflammatory diseases including asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome. | 2009-12-10 |
20090306083 | Use of Trifluoromethyl Substituted Benzamides in teh Treatment of Neurological Disorders - The invention relates to methods of using the compounds of the invention, including trifluoromethyl substituted benzamide compounds and salts thereof, as well as pharmaceutical compositions comprising the same, in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders. The invention also relates to modulating the activity of an Eph receptor in a cell, stimulating neural regeneration, and reversing neuronal degeneration, by administering a compound of the invention to a cell or subject in an effective amount. | 2009-12-10 |
20090306084 | HETEROARYL 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS - Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: | 2009-12-10 |
20090306085 | HCV PROTEASE INHIBITORS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2009-12-10 |
20090306086 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR - Compounds active on Fms and/or Kit protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of Fms and/or Kit protein kinases. | 2009-12-10 |
20090306087 | Compounds and Methods for Kinase Modulation, and Indications Therefor - Compounds and salts thereof, formulations thereof conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of Raf protein kinases, including melanoma, colorectal cancer, thyroid cancer, ovarian cancer, cholangiocarcinoma, pain or polycystic kidney disease. | 2009-12-10 |
20090306088 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES - A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof are disclosed and claimed. | 2009-12-10 |
20090306089 | COMPOUNDS - Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof: | 2009-12-10 |
20090306090 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS - Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): | 2009-12-10 |
20090306091 | ANTIMALARIAL THERAPY USING A COMBINATION OF SYNTHETIC ARTEMISININ DERIVATIVE AND BISQUINOLINE DERIVATIVE - The technical field of the present invention relates to antimalarial therapy using a synthetic artemisinin derivative and bisquinoline derivative. | 2009-12-10 |
20090306092 | METHOD FOR TREATING COGNITIVE DEFICITS - The invention relates to methods of treating cognitive dysfunction and improving cognitive functioning comprising the administration of trans-4-((1R,3S)-6-chloro-3-phenylindan- | 2009-12-10 |
20090306093 | METHOD FOR TREATING PATIENT HAVING BENIGN PROSTATE HYPERPLASIA - A method for treating a patient having lower urinary tract symptoms is provided. The method comprises a step of administering to the patient a therapeutically effective amount of one selected from a group consisting of a treating compound of 7-[2-[4-(2-Chlorobenzene)piperazinyl]ethyl]-1,3-dimethyl xanthine, a salt of the treating compound, a solvate of the treating compound and a combination thereof, wherein the compound has an effect on treating the benign prostate hyperplasia via a mechanism selected from a group consisting of an activation of PKG pathway, a blockage of an adrenoceptor, an opening of a potassium channel and an inhibition of PDE activity. | 2009-12-10 |
20090306094 | Methods Of Identifying And Treating Individuals Exhibiting Mutant Bcr/Abl Kinase Polypeptides - The present invention relates to mutant BCR-ABL kinase proteins, and to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that express such mutant BCR-ABL kinase proteins. | 2009-12-10 |
20090306095 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES - This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. | 2009-12-10 |
20090306096 | Novel Isoxazoles and Methods of Use Thereof - The invention relates to isoxazole derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions. | 2009-12-10 |
20090306097 | Use of allopurinol for the treatment of palmar plantar erythrodysesthesia - Allopurinol or a pharmaceutically acceptable salt thereof can be used for the treatment or prevention of palmar plantar erythrodysesthesia induced by chemotherapy. The allopurinol or its salt may be administered topically to the affected areas, palms and soles, preferably in the form of a cream. | 2009-12-10 |
20090306098 | COMBINATION OF ROSCOVITINE AND A HDCA INHIBITOR TO TREAT PROLIFERATIVE DISEASES - A first aspect of the invention relates to a combination comprising roscovitine, or a pharmaceutically acceptable salt thereof, and a HDAC inhibitor selected from sodium butyrate, or a prodrug thereof, suberoylanilide hydroxamic acid (SAHA), sodium valproate and trichostatin A (TSA). A second aspect of the invention relates to a pharmaceutical product comprising roscovitine, or a pharmaceutically acceptable salt thereof, and a HDAC inhibitor selected from sodium butyrate, or a prodrug thereof, suberoylanilide hydroxamic acid (SAHA), sodium valproate and trichostatin A (TSA) as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method for treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering roscovitine, or a pharmaceutically acceptable salt thereof, and a HDAC inhibitor selected from sodium butyrate, or a prodrug thereof, suberoylanilide hydroxamic acid (SAHA), sodium valproate and trichostatin A (TSA) to a subject. | 2009-12-10 |
20090306099 | Method of Screening for Drug Hypersensitivity Reaction - Methods of assessing the risk of clinical signs of hypersensitivity reaction to nucleoside antiviral compounds, including abacavir, are described. The methods include genotyping subjects for polymorphisms in the TNFα gene, the class 1 HLA genes, or a combination of both the TNFα and HLA genes. | 2009-12-10 |
20090306100 | METHODS OF TREATING SCHIZOPHRENIA - This invention relates to methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | 2009-12-10 |
20090306101 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS - The invention relates to a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amounts of: (1) a compound 1 of formula (I), wherein the groups R | 2009-12-10 |
20090306102 | 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES - This invention relates to novel pyridinyl-quinazoline derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels. | 2009-12-10 |
20090306103 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS - Pyridonecarboxamide derivatives, pharmaceutical compositions which contain the same and methods for treating hyper-proliferative disorders and angiogenesis disorders using the same. | 2009-12-10 |
20090306104 | Use of Lck inhibitors for treatment of immunologic diseases - The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component. | 2009-12-10 |
20090306105 | Bicyclic heterocycles, medicaments containing these compounds, their use and process for preparing them - The present invention relates to bicyclic heterocycles of the general formula (I), their tautomers, their stereoisomers, their mixtures and their salts, in particular physiologically tolerable salts with inorganic or organic acids, which have valuable pharmacological properties, in particular an inhibiting action on the signal transduction transmitted by tyrosinekinases, their use for the treatment of illnesses, in particular tumours and also benign prostatic hyperplasia (BPH), of disorders of the lungs and the bronchia and their preparation. | 2009-12-10 |
20090306106 | FORMS OF CRYSTALLINE LAPATINIB AND PROCESSES FOR PREPARATION THEREOF - The present invention provides new crystalline forms of lapatinib base, Form X and Form Y, and amorphous lapatinib base, pharmaceutical compositions comprising the new crystalline forms of lapatinib base, and/or the amorphous lapatinib base, and processes for their preparation. | 2009-12-10 |
20090306107 | Organic Compounds - The present invention relates to compounds that are useful to inhibit, regulate and/or modulate tyrosine and serine/threonine kinase and kinase-like proteins, such as RAF kinase, a serine/threonine kinase that functions in the MAP kinase signaling pathway. The application is also concerned with compositions which contain these compounds, and methods of using them to treat tyrosine and serine/threonine kinase and kinase-like dependent diseases, such as angiogenesis, cancer and cardiac hypertrophy, and with other subject matter. | 2009-12-10 |
20090306108 | SUBSTITUTED PYRIMIDINONES - Disclosed are compounds Formula I | 2009-12-10 |
20090306109 | FUNGICIDE ACTIVE SUBSTANCE COMBINATIONS - The novel active compound combinations comprising 2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-[1,2,4]-triazole-3-thione of the formula | 2009-12-10 |
20090306110 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR - The present invention provides compounds of formula (I), which are antagonists of the 5-HT | 2009-12-10 |
20090306111 | Pharmaceutical Comprising PPAR Agonist - An object of the present invention is to provide an agent for promoting proliferation of a meibomian gland epithelial cell and a corneal epithelial cell, as well as provide an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye. | 2009-12-10 |
20090306112 | ANTIVIRAL PROTEASE INHIBITORS - The invention is related to compounds of Formula I or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds. | 2009-12-10 |
20090306113 | PHARMACEUTICAL FORMULATION - The present invention provides enteric polymer coated tablet formulations for oral administration which comprise a phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 (Lp-PLA2) inhibitor, processes for preparing such formulations and their use in therapy, in particular the treatment of atherosclerosis. | 2009-12-10 |
20090306114 | Polymorphic and Other Crystalline Forms of Cis-FTC - Solid phases of (−)-cis-FTC, which are designated herein as amorphous (−)-FTC and Forms II and III (−)-cis-FTC) are provided that can be distinguished from Form I (−)-cis-FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. A hydrated crystalline form of (±)-cis-FTC (i.e. racemic cis-FTC), and a dehydrated form of the hydrate, are also provided, and can similarly be distinguished from other forms of FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These FTC forms can be used in the manufacture of other forms of FTC, or in pharmaceutical compositions. Particularly preferred uses of these forms are in the treatment of HIV or hepatitis B. | 2009-12-10 |
20090306115 | Phenyl ethyne compounds - In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted or unsubstituted six membered heterocyclic ring that includes at least two nitrogen atoms. The ring additionally includes four carbon atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon triple bond. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system. Invention compounds may also act as insecticides, and as fungicides. Pharmaceutical compositions containing invention compounds also have wide utility. | 2009-12-10 |
20090306116 | PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY - A compound of formula (I) wherein the substituents are as defined in the text for use in inhibiting insulin-like growth factor 1 receptor activity in a warm blooded animal such as man. | 2009-12-10 |
20090306117 | ROSUVASTATIN ZINC SALT - The present invention is related to rosuvastatin zinc salt of the Formula (I), process for preparation thereof and medicinal products containing said salt. Rosuvastatin zinc salt according to the present invention is prepared by reacting rosuvastatin with a zinc alcoholate, zinc enolate or an inorganic or organic zinc salt and isolating the thus obtained rosuvastatin zinc salt (2:1). | 2009-12-10 |
20090306118 | Trisubstituted Thiophenes as Progesterone Receptor Modulators - The present invention is directed to novel trisubstituted thiophene derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by agonists and antagonists of the progesterone receptor. The clinical usage of these compounds are related to hormonal contraception, the treatment and/or prevention of secondary dysmenorrhea, amenorrhea, dysfunctional uterine bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon or prostate. Additional uses of the invention include stimulation of food intake. | 2009-12-10 |